Announced details
Third-line treatment for pancreatic cancer, cancer immunotherapy, solid and hematological cancers, research into novel COVID-19 treatments, and anticancer drug research and development
The primary endpoint of a 3-month progression-free survival rate was achieved in Groups 1 and 2 of the CBP501 Phase 2 clinical trial. Other efficacy figures are not disclosed.
CBP501 achieved its primary endpoint in a Phase 2 clinical trial. CBS9106 completed a Phase 1 clinical trial. Cumulative numbers of licenses introduced and users are not disclosed.
The company has an allotment and borrowing relationship with SBI Securities Co., Ltd. under the stock acquisition rights and loan agreements. It has a joint research relationship with Shizuoka Prefectural University. It has an AI-based drug discovery joint research relationship with INTAGE Healthcare Inc. Stemline previously held a license to CBS9106, but the agreement was terminated in June 2025 and all rights were returned.
SBI Securities Co., Ltd. is the allottee of the stock acquisition rights and the lender under the loan. Shizuoka Prefectural University is the joint research partner for IDO/TDO dual inhibitors. INTAGE Healthcare Inc. is the joint research partner for AI-based drug discovery. Stemline was the former licensee of CBS9106. Other details, including location, representative, capital and year established, are not disclosed.
CBP501 orphan drug designation
Exclusive protection for 10 years in Europe and 7 years in the United States through orphan drug designation. Registration number is not disclosed.
2-2-1 Otemachi, Numazu, Shizuoka (head office)
Expected proceeds of ¥4,175 million (after deducting ¥22 million in issuance expenses), and a loan commitment limit of ¥500 million. The upfront payments under the CBS9106 agreement were ¥10 million and ¥5 million, and cumulative technical advisory fees were ¥702 million.
No business revenue was recorded in the fiscal year ended June 2026. Operating loss was ¥1,358 million, ordinary loss was ¥1,307 million, and net loss was ¥1,308 million. Additional basic research on CBS9106 will be conducted within the basic research budget, so there is no short-term impact on performance.
The company does not address Offering price.
IARC GLOBOCAN2018; ECIS European Cancer Information System Globocan 2022; NCCN Clinical Practice Guidelines in Oncology; Anticancer Research; Oncologist; Cancer Research and Clinical Oncology; Cancer Medicine; Journal of Clinical Oncology; Therapeutics and Clinical Risk Management; ESMO2020; materials from the Central Social Insurance Medical Council General Meeting of the Ministry of Health, Labour and Welfare; ASHP
| Item | Details |
|---|---|
| Names of Products / Services Covered | CBP501, CBT005, CBS9106（Felezonexor）, CBP-A08, IDO/TDO dual inhibitor |
| Counterparty | SBI SECURITIES CO., LTD., Shizuoka Prefectural University, INTAGE Healthcare, Stemline |
| Counterparty overview | SBI Securities Co., Ltd. is the allottee of the stock acquisition rights and the lender under the loan. Shizuoka Prefectural University is the joint research partner for IDO/TDO dual inhibitors. INTAGE Healthcare Inc. is the joint research partner for AI-based drug discovery. Stemline was the former licensee of CBS9106. Other details, including location, representative, capital and year established, are not disclosed. |
| Relationship with the Company | The company has an allotment and borrowing relationship with SBI Securities Co., Ltd. under the stock acquisition rights and loan agreements. It has a joint research relationship with Shizuoka Prefectural University. It has an AI-based drug discovery joint research relationship with INTAGE Healthcare Inc. Stemline previously held a license to CBS9106, but the agreement was terminated in June 2025 and all rights were returned. |
| Contract Value | Expected proceeds of ¥4,175 million (after deducting ¥22 million in issuance expenses), and a loan commitment limit of ¥500 million. The upfront payments under the CBS9106 agreement were ¥10 million and ¥5 million, and cumulative technical advisory fees were ¥702 million. |
| Contract Date | The loan agreement is scheduled to be dated 2 November 2026. The CBS9106 license-out took place in December 2014, the covered territory was expanded in August 2018, and the agreement was terminated and all rights returned in June 2025. |
| Launch date | The start date of the CBP501 European Phase 3 clinical trial is not disclosed. The loan agreement is scheduled to run from 2 November 2026 to 7 May 2027. The exercisable period for the stock acquisition rights is from 2 November 2026 to 2 November 2028. |
| Applicable area | Third-line treatment for pancreatic cancer, cancer immunotherapy, solid and hematological cancers, research into novel COVID-19 treatments, and anticancer drug research and development |
| Award/certification name | CBP501 orphan drug designation |
| Registration number and expiry date | Exclusive protection for 10 years in Europe and 7 years in the United States through orphan drug designation. Registration number is not disclosed. |
| Location | 2-2-1 Otemachi, Numazu, Shizuoka (head office) |
| Location scale | 19 employees (14 in research and development and 5 in administration). The head office houses a research facility and an animal testing facility. |
| Quantitative Effects | The primary endpoint of a 3-month progression-free survival rate was achieved in Groups 1 and 2 of the CBP501 Phase 2 clinical trial. Other efficacy figures are not disclosed. |
| Usage history | CBP501 achieved its primary endpoint in a Phase 2 clinical trial. CBS9106 completed a Phase 1 clinical trial. Cumulative numbers of licenses introduced and users are not disclosed. |
| Impact on Business Performance | No business revenue was recorded in the fiscal year ended June 2026. Operating loss was ¥1,358 million, ordinary loss was ¥1,307 million, and net loss was ¥1,308 million. Additional basic research on CBS9106 will be conducted within the basic research budget, so there is no short-term impact on performance. |
| Source | IARC GLOBOCAN2018; ECIS European Cancer Information System Globocan 2022; NCCN Clinical Practice Guidelines in Oncology; Anticancer Research; Oncologist; Cancer Research and Clinical Oncology; Cancer Medicine; Journal of Clinical Oncology; Therapeutics and Clinical Risk Management; ESMO2020; materials from the Central Social Insurance Medical Council General Meeting of the Ministry of Health, Labour and Welfare; ASHP |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To fund front-loaded investment spending beginning before and around approval to start the European Phase 3 clinical trial, and to cover most of the funding requirements through completion of the CBP501 Phase 3 clinical trial.